[1] FERREIRA C N, MARINHO R T, CORTEZ-PINTO H, et al.Incidence, predictive factors and clinical significance of development of portal vein thrombosis in cirrhosis:a prospective study[J].Liver Int, 2019, 39(8):1459-1467.
[2] VIOLI F, CORAZZA G R, CALDWELL S H, et al.Incidence and recurrence of portal vein thrombosis in cirrhotic patients[J].Thromb Haemost, 2019, 119(3):496-499.
[3] ROSENQVIST K, ERIKSSON L G, RORSMAN F, et al.Endovascular treatment of acute and chronic portal vein thrombosis in patients with cirrhotic and non-cirrhotic liver[J].Acta Radiol, 2016, 57(5):572-579.
[4] NORTHUP P G, GARCIA-PAGAN J C, GARCIA-TSAO G, et al.Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease:2020 practice guidance by the american association for the study of liver diseases[J].Hepatology, 2021, 73(1):366-413.
[5] BHANGUI P, LIM C, LEVESQUE E, et al.Novel classification of non-malignant portal vein thrombosis:a guide to surgical decision-making during liver transplantation[J].J Hepatol, 2019, 71(5):1038-1050.
[6] SALEM R, VOUCHE M, BAKER T, et al.Pretransplant portal vein recanalization-transjugular intrahepatic portosystemic shunt in patients with complete obliterative portal vein thrombosis[J].Transplantation, 2015, 99(11):2347-2355.
[7] INTAGLIATA N M, CALDWELL S H, TRIPODI A.Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis[J].Gastroenterology, 2019, 156(6):1582-1599.e1.
[8] VALENTIN N, KORRAPATI P, CONSTANTINO J, et al.The role of transjugular intrahepatic portosystemic shunt in the management of portal vein thrombosis:a systematic review and meta-analysis[J].Eur J Gastroenterol Hepatol, 2018, 30(10):1187-1193.
[9] GARCÍA-PAGÁN J C, SAFFO S, MANDORFER M, et al.Where does TIPS fit in the management of patients with cirrhosis?[J].JHEP Rep, 2020, 2(4):100122.
[10] SUN X Y, WANG G C, WANG J, et al.Transjugular intrahepatic portosystemic shunt is effective in patients with chronic portal vein thrombosis and variceal bleeding[J].Hepatobiliary Pancreat Dis Int, 2021, 20(2):128-136.
[11] HAN G, QI X, HE C, et al.Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis[J].J Hepatol, 2011, 54(1):78-88.
[12] KLINGER C, RIECKEN B, SCHMIDT A, et al.Transjugular portal vein recanalization with creation of intrahepatic portosystemic shunt(PVR-TIPS) in patients with chronic non-cirrhotic, non-malignant portal vein thrombosis[J].Z Gastroenterol, 2018, 56(3):221-237.
[13] QI X, HE C, GUO W, et al.Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with variceal bleeding in liver cirrhosis:outcomes and predictors in a prospective cohort study[J].Liver Int, 2016, 36(5):667-676.
[14] STINE J G, WANG J, SHAH P M, et al.Decreased portal vein velocity is predictive of the development of portal vein thrombosis:a matched case-control study[J].Liver Int, 2018, 38(1):94-101.
[15] MOLVAR C, AMIN P.Portal vein thrombosis in cirrhosis:interventional treatment options[J].Curr Gastroenterol Rep, 2021, 23(12):24.
[16] ZHENG D, YU J, LI H, et al.Effects of transjugular intrahepatic portosystemic shunt treatment of patients with liver cirrhosis and portal hypertension:case series[J].Medicine(Baltimore), 2021, 100(27):e26610.
[17] WANG H L, LU W J, ZHANG Y L, et al.Comparison of transjugular intrahepatic portosystemic shunt in the treatment of cirrhosis with or without portal vein thrombosis:a retrospective study[J].Front Med(Lausanne), 2021, 8:737984.
[18] KLINGER C, RIECKEN B, SCHMIDT A, et al.Transjugular local thrombolysis with/without TIPS in patients with acute non-cirrhotic, non-malignant portal vein thrombosis[J].Dig Liver Dis, 2017, 49(12):1345-1352.
[19] LUCA A, MIRAGLIA R, CARUSO S, et al.Short-and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis[J].Gut, 2011, 60(6):846-852.
[20] THORNBURG B, DESAI K, HICKEY R, et al.Pretransplantation portal vein recanalization and transjugular intrahepatic portosystemic shunt creation for chronic portal vein thrombosis:final analysis of a 61-patient cohort[J].J Vasc Interv Radiol, 2017, 28(12):1714-1721.e2.
[21] RODRIGUES S G, SIXT S, ABRALDES J G, et al.Systematic review with meta-analysis:portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis[J].Aliment Pharmacol Ther, 2019, 49(1):20-30.
[22] ZHANG J B, CHEN J, ZHOU J, et al.Systematic review and meta-analysis of trans-jugular intrahepatic portosystemic shunt for cirrhotic patients with portal vein thrombosis[J].World J Clin Cases, 2021, 9(19):5179-5190.
[23] ANGELI P, BERNARDI M, VILLANUEVA C, et al.EASL clinical practice guidelines for the management of patients with decompensated cirrhosis[J].J Hepatol, 2018, 69(2):406-460.
[24] YEOH S W, KOK H K.Transjugular intrahepatic portosystemic shunts in portal vein thrombosis:a review[J].J Dig Dis, 2021, 22(9):506-519.
[25] VIZZUTTI F, SCHEPIS F, ARENA U, et al.Transjugular intrahepatic portosystemic shunt(TIPS):current indications and strategies to improve the outcomes[J].Intern Emerg Med, 2020, 15(1):37-48.
[26] GABALLA D, BEZINOVER D, KADRY Z, et al.Development of a model to predict portal vein thrombosis in liver transplant candidates:the portal vein thrombosis risk index[J].Liver Transpl, 2019, 25(12):1747-1755.
[27] INTAGLIATA N M, ARGO C K, STINE J G, et al.Concepts and controversies in haemostasis and thrombosis associated with liver disease:proceedings of the 7th international coagulation in liver disease conference[J].Thromb Haemost, 2018, 118(8):1491-1506.
[28] THORNBURG B, DESAI K, HICKEY R, et al.Portal vein recanalization and transjugular intrahepatic portosystemic shunt creation for chronic portal vein thrombosis:technical considerations[J].Tech Vasc Interv Radiol, 2016, 19(1):52-60.
[29] ALZUBAIDI S, PATEL I, SAINI A, et al.Current concepts in portal vein thrombosis:etiology, clinical presentation and management[J].Abdom Radiol(NY), 2019, 44(10):3453-3462.
[30] MATSUSHIMA H, FUJIKI M, SASAKI K, et al.Can pretransplant TIPS be harmful in liver transplantation? a propensity score matching analysis[J].Surgery, 2020, 168(1):33-39.
[31] DONG F, LUO S H, ZHENG L J, et al.Incidence of portal vein thrombosis after splenectomy and its influence on transjugular intrahepatic portosystemic shunt stent patency[J].World J Clin Cases, 2019, 7(17):2450-2462.
[32] LV Y, BAI W, LI K, et al.Anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis:a prospective observational study[J].Am J Gastroenterol, 2021, 116(7):1447-1464.
[33] WANG Q, LV Y, BAI M, et al.Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding[J].J Hepatol, 2017, 67(3):508-516.
[34] TREBICKA J, BASTGEN D, BYRTUS J, et al.Smaller-diameter covered transjugular intrahepatic portosystemic shunt stents are associated with increased survival[J].Clin Gastroenterol Hepatol, 2019, 17(13):2793-2799.e1.
[35] RAJESH S, GEORGE T, PHILIPS C A, et al.Transjugular intrahepatic portosystemic shunt in cirrhosis:an exhaustive critical update[J].World J Gastroenterol, 2020, 26(37):5561-5596.
[36] RIGGIO O, RIDOLA L, ANGELONI S, et al.Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters:results of a randomized controlled trial[J].J Hepatol, 2010, 53(2):267-272.
[37] ZHAN C, PRABHU V, KANG S K, et al.Comparison of non-tumoral portal vein thrombosis management in cirrhotic patients:tips versus anticoagulation versus no treatment[J].J Clin Med, 2021, 10(11):2316.
[38] WANG Z, JIANG M S, ZHANG H L, et al.Is post-tips anticoagulation therapy necessary in patients with cirrhosis and portal vein thrombosis? A randomized controlled trial[J].Radiology, 2016, 279(3):943-951. |
